Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

por Goto, Koichi, Shiraishi, Yoshimasa, Murakami, Haruyasu, Horinouchi, Hidehito, Toyozawa, Ryo, Takeda, Masayuki, Uno, Makiko, Crawford, Nigel, McGill, Joseph, Jimbo, Takeshi, Ishigami, Masato, Takayama, Gensuke, Nakayama, Shintaro, Ohwada, Shoichi, Nishio, Makoto
Publicado 2023

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a mul...

por Yang, James Chih-Hsin, Su, Wu-Chou, Chiu, Chao-Hua, Shiah, Her-Shyong, Lee, Kang-Yun, Hsia, Te-Chun, Uno, Makiko, Crawford, Nigel, Terakawa, Hiroshi, Chen, Wen-Chi, Takayama, Gensuke, Hsu, Ching, Hong, Ying, Saintilien, Carline, McGill, Joseph, Chang, Gee-Chen
Publicado 2023